Categories
Blog

Pharmacodynamics and Pharmacokinetics: The Science Behind Drug Action (Understanding the different characteristics of a drug and how they are important for therapeutic success)

The Science Behind Drug Action

Medical professionals, researchers, and especially pharmaceutical sales representatives can benefit from understanding how drugs work in the body. Their role involves presenting complex drug information to healthcare professionals who rely on this knowledge to make informed prescribing decisions. They could also better list a drug’s benefits over its competitors. Learning pharmacokinetics (PK) and pharmacodynamics (PD) concepts can give sales reps a better understanding of how drugs reach therapeutic levels while minimizing risks. 

Imagine a patient who takes ibuprofen to treat a headache. After swallowing the pill, it dissolves in the stomach and passes through the intestines where it gets absorbed. Once in the bloodstream, it is transported to its target tissues, inhibiting enzymes (like COX-2) that cause pain and inflammation.2 Eventually, the liver metabolizes the drug, and the kidneys excrete it via urine. This entire process illustrates how PK and PD work together.

A drug’s solubility, how the liver metabolizes it, and patient-specific factors like genetics can influence the journey of a drug. For example, a patient with CKD (chronic kidney disease) will have diminished clearance of medications that require the kidney to be excreted; if dose adjustments based on this altered clearance are not made, they would be at high risk for drug accumulation and toxicity. These details are the reasons why knowledge of PK and PD is fundamental to making every drug both effective and safe for every patient.3

Pharmacokinetics

PK focuses on what the body does to a drug. It has four main steps:

  1. Absorption: The drug enters the bloodstream from the site of administration. Factors like the formulation (liquid vs. tablet), route (oral vs. IV), and the patient’s gastrointestinal health (gastric pH) can influence how quickly this happens.2
  2. Distribution: Following absorption, the drug is delivered to other parts of the body (cells/tissues). For instance, highly lipophilic drugs have an easier time crossing the blood-brain barrier, eliciting effects on the central nervous system, while others may remain mostly in the bloodstream.3
  3. Metabolism: A process by which the body can detoxify or transform drugs or chemicals. Metabolism can activate or inactivate drugs by modifying its chemical structure. A common example is how codeine must be metabolized into morphine for pain relief.2
  4. Excretion: The drug and its metabolites are removed from the body, primarily via urine or bile but in smaller quantities through saliva, breast milk, and sweat. Impaired kidney function can slow this process, requiring dose adjustments to prevent toxicity.3

Together, these processes determine the drug’s concentration in the bloodstream and tissues over time, directly impacting its effectiveness and safety.

Pharmacodynamics

PD examines what a drug does to the body.  Key concepts include:

  • Receptor Binding: Most drugs act by binding to specific receptors that cause a biological response to occur. Beta-blockers reduce heart rate and blood pressure; to “work,” these agents must bind to adrenergic receptors in the body.2
  • Dose-Response: The drug’s concentration at the target location typically determines the response there. There is frequently a threshold, beyond which raising the dosage has no further advantages and only raises the possibility of adverse effects.3
  • Therapeutic Index: The proportion between an effective dose and a toxic dose. Therapeutic drug monitoring is used to obtain peak and trough levels to determine drug serum concentration which tells us if a drug is efficacious or is leading to toxic levels. A wider therapeutic index, as seen with drugs like amoxicillin, offers more flexible dosing compared to drugs like warfarin, which require precise monitoring.2 

Pharmacodynamics helps us understand how a drug works, how much it is needed for the desired effect, and what potential risks or adverse effects may be associated with its use.

The PK-PD Interaction: A Dynamic Duo

Pharmacokinetics determines the drug’s availability at the site of action, while pharmacodynamics determines its biological impact. For example, a drug with poor absorption (PK) may not reach therapeutic levels, regardless of its potency (PD). A highly effective drug (PD) may pose safety concerns if it accumulates due to slow metabolism or excretion (PK).

The relationship is crucial in:

  • Dosing: Ensuring the right amount of drug provides benefits without causing harm, such as adjusting vancomycin doses to prevent nephrotoxicity.3
  • Managing Side Effects: Balancing drug exposure and effect to achieve desired outcomes. This is especially critical in oncology, where chemotherapeutic agents require precise dosing to improve survival while minimizing side effects.2
  • Combination Therapies: Understanding PK-PD relationships helps in predicting drug-drug interactions and adjusting treatment regimens accordingly.3

Emerging Trends and Applications

Technological and research developments widen the limits of PK/PD. In personalized medicine, genetic information is used to tailor treatment regimens.  

  • Pharmacogenomics: Treatments can be customized to meet the needs of each patient by examining how genes affect drug response. For instance, genetic testing for CYP2C19 enzyme activity determines the appropriate dosage of clopidogrel.4
  • Biologics: monoclonal antibodies pose PK challenges due to their large size and complex metabolism. Equally important is understanding PD to optimize the therapeutic effects against specific molecular targets, for example, tumor necrosis factor (TNF) in the treatment of autoimmune disorders.5

Patient-Specific Factors

Individual characteristics significantly influence how drugs are processed and work:

  • Age: due to reduced drug clearance, neonates and infants require lower doses of medication to avoid toxicity (e.g. aminoglycosides).  Similarly, the elderly population has an increased risk of accumulation due to slowed drug metabolism and excretion (e.g. benzodiazepines).6 
  • Weight: underweight and obese patients may require dose adjustments due to altered volumes of distribution. Weight-based medications, like vancomycin, are usually based on adjusted body weight versus actual body weight to ensure efficacy without toxicity.6  
  • Kidney: kidney function is measured by creatinine clearance (CrCl) or estimated glomerular filtration rate (eGFR). Reduced kidney function affects the elimination of really excreted drugs, like aminoglycosides. Drug doses and/or intervals need to be adjusted to prevent accumulation and toxicity.6 
  • Liver: liver function is determined by liver function tests (LFTs), which measure the levels of enzymes and proteins made by the liver. The impaired liver function reduces the metabolism of drugs processed by hepatic enzymes (e.g. warfarin) which leads to higher plasma concentrations.6   
  • Comorbidities: patients diagnosed with diabetes have the possibility of developing gastroparesis also known as delayed gastric emptying which can slow the absorption of drugs taken orally (e.g. metformin).6  

Relevance in Pharmaceutical Roles 

A strong understanding of PK and PD is extremely useful for pharma sales reps because this knowledge fosters more informed conversations with HCPs, increasing the likelihood of successful communication about their products. Understanding a drug’s onset of action, duration, and therapeutic effects helps reps to align product benefits with patient needs effectively. For sales representatives, the PRC and CSPP certifications can enhance this understanding and communication with HCPs:

  • Pharmaceutical Representative Certification (PRC): This certification provides professionals with a foundational knowledge of pharmacology, regulatory standards, and effective communication strategies. A solid grasp of PK and PD is essential for explaining drug benefits and safety to healthcare professionals.1
  • Certified Specialty Pharma Professional (CSPP): This certification dives deeper into the clinical and scientific aspects of pharmaceuticals, including more complex products such as biologics and biosimilars. 

Ensuring Therapeutic Success

An understanding of PK and PD is essential to ensuring therapeutic success. By learning these concepts, healthcare professionals can:

  • Develop safer and more effective drugs.
  • Tailor treatments to individual patient needs.
  • Reduce the risks of adverse effects and drug interactions.
  • Improve communication between healthcare providers, patients, and pharmaceutical stakeholders.

PK and PD continue to be essential for drug development and patient care in the era of personalized medicine and advanced therapeutics. These principles guide strategic decisions for healthcare policies and resource distribution, ensuring that treatments are both clinically effective and cost-effective. 7

Conclusion

The journey of a drug demonstrates the balance of PK and PD. Expanding our knowledge of how drugs work allows us to promote advancements in therapy, research, and patient care. For sales professionals in the pharmaceutical industry, certifications like PRC and CSPP provide opportunities to improve their knowledge and excel in their careers. By applying the principles of PK and PD, we can continue to make advancements in healthcare and improve patient outcomes.


References

  1. ACMALifeSciences. “Training and Certification Programs.” Accessed January 3, 2025. https://acmalifesciences.org/training
  2. Rang, H. P., Dale, M. M., Ritter, J. M., Flower, R. J., & Henderson, G. (2019). Rang & Dale’s Pharmacology. 9th Edition. Elsevier. pp. 4-32, 117-162.
  3. Goodman, L. S., & Gilman, A. G. (2021). The Pharmacological Basis of Therapeutics. 13th Edition. McGraw-Hill Education. pp. 14-51.
  4. T P A, Sekhar S, Jose A, et al. Pharmacogenomics: The Right Drug to the Right Person. Journal of Clinical Medicine Research. 2009;1(4). doi:https://doi.org/10.4021/jocmr2009.08.1255
  5. Kothari M, Wanjari A, Acharya S, et al. A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach. Cureus. 2024;16(6). doi:https://doi.org/10.7759/cureus.61983
  6. Mangoni AA, Jackson SHD. Age-related Changes in Pharmacokinetics and Pharmacodynamics: Basic Principles and Practical Applications. British Journal of Clinical Pharmacology. 2004;57(1):6-14. doi:https://doi.org/10.1046/j.1365-2125.2003.02007.x
  7. Srinivasan M, White A, Chaturvedula A, et al. Incorporating Pharmacometrics into Pharmacoeconomic Models: Applications from Drug Development. Pharmacoeconomics. 2020;38(10):1031-1042. doi:https://doi.org/10.1007/s40273-020-00944-0
  8. Gleichmann N. What Is ADME? Drug Discovery from Technology Networks. Published June 26, 2020. https://www.technologynetworks.com/drug-discovery/articles/what-is-adme-336683 (image)
Categories
Blog

Biosimilars: A Promising Solution for Affordable Access to Biologic Therapies

Biosimilars: The Future of Affordable Biologic Therapies

Biologics are some of the most expensive forms of therapy in modern healthcare. These high prices are the result of multiple factors: they’re derived from living organisms making them sensitive and complex for both manufacturers and patients, research requires advanced technology to test for safety and effectiveness, and they’re in high demand without much competition. Prices can range anywhere from $3,000 a year for asthma, eczema, and allergy treatments to $100,000 or more per year for certain cancers. While biologics only account for 2% of overall prescriptions, they contribute to 37% of net drug spending [1]. This can make these treatment options much less accessible to the general public as it forces many healthcare professionals and insurance companies to rule them out for cheaper, possibly inferior, formulations. However, there are products that can help bridge the affordability gap created by these biologics, while also providing similar efficacy and safety for patient treatment.

The Cost-Saving Alternative: What are Biosimilars?

Biosimilars are biologic formulations that are very similar to a reference biologic product already approved by the FDA. Biologic products can’t be recreated exactly because of the inherent variation that exists within living organisms that biologics are derived from.  Therefore biosimilars are formulated in such a way that there are no clinically meaningful differences between each biosimilar and their reference product in terms of safety, efficacy, and potency, and the FDA does rigorous testing and evaluation to ensure this before approval. [2]

Some biologics are very effective treatments for specific disease states like autoinflammatory disorders, and some may be the best known treatments for those conditions. However, the high prices of these patented formulations make it difficult for patients to gain access to the best possible treatment for their condition. Some products may be too costly for insurance to cover, while others might require use of other medications first or even prior authorizations that need approval before giving access to patients. The existence of biosimilars is meant to address both the cost and access of biologics in the healthcare industry. [1][2]

Fortunately biosimilars are much less expensive than their reference product and multiple biosimilars can be created for one reference biologic by different companies, making these formulations more easily accessible to patients. Also, since the biosimilars are evaluated to have similar safety and efficacy to their base product, healthcare providers can feel safer prescribing these formulations, knowing that their patients are receiving the most effective regimens without having to worry as much about their cost. Insurances would be more willing to cover those prices and give lower copays for patients thanks to the improved cost-effectiveness of these formulations, as well as the fact that more hospitals would be able to place them on their formularies due to better accessibility and lower costs. [1][2]

The Challenges of Biosimilars

While biosimilars seem like an obvious answer to this pricing and accessibility issue with biologics, their existence doesn’t automatically warrant their use or a secure place for them in the market. The approval of new biosimilars and the process of finding a place for them in the healthcare space will have its own set of challenges:

  • Physician Trust: Biologics are more well-known and trusted by physicians who have been exposed to them for years. Newer biosimilars and even possibly their manufacturers will not enter the market with that same trust to use their product. Companies will have to make an effort to communicate with these healthcare professionals, informing them of their product and helping them feel more confident in recommending it to their patients.
  • Market Competition: Another similarity that biosimilars have to generics is that there can be multiple biosimilars for the same reference product, leading to competition for shares in the market. Without good advertising or a strong market presence, these biosimilars can easily be overlooked and not see as much use.
  • Lack of Post-Market Data: Very new biosimilars will have little to no post-market reports of their use once approved by the FDA. This makes it challenging to recommend as many HCPs may not want to take what they see as a risk with this product if it hasn’t seen official use in the market yet.

Biosimilars don’t have a predetermined path to use in treatments once they’re approved by the FDA, but proper communication with physicians and establishing their presence in the market can help them find their place in the healthcare system. Newer or less prominent manufacturers will struggle the most with these challenges, but there are teams with the experience and tools to overcome these obstacles and get more biosimilars into the pharma market.

Pharma Companies and Biosimilars

Pharma companies with established products and who have already formed connections with healthcare professionals can overcome some of these challenges and they have the resources to accrue this data and present it properly to physicians. In fact, 50% of the global market for biosimilars is dominated by large pharmaceutical companies such as Pfizer, Sandoz, and Amgen, who are known to have worldwide reach and top of the line research and development capabilities to maximize market access. [4]

One example in the United States is Samsung Bioepis, a biopharmaceutical company whose mission statement is to accelerate access to biologics by “bringing high-quality, clinically proven biosimilars to patients who need them.” The company was able to launch 41 new biosimilars into the US market during 2024. Their biosimilar market trends over 2024 have shown a 53% average increase in market share within 5 years post launch of each product, while average sale prices also decreased by around 53% within 5 years. [3]

In terms of worldwide growth, the global market value for biosimilars has increased consistently over the last 5 years. Starting in 2019, the US market was valued at $4.5 billion and the European market at $7 billion, as the two nations led this growth to $9.3 billion and $13 billion in 2023, respectively. The global biosimilars market is projected to grow beyond $68 billion by 2028, as more biologic patents are set to expire and generic manufacturers are expected to enter and evolve the market with their business practices. [4]

Pharma or BioPharma companies would also benefit from having certified professionals equipped with expertise in biologics and biosimilars to take this information, apply it to further research, development, and marketing, and communicate it properly to healthcare professionals. A Board Certified Biologics and Biosimilar Specialist (BCBBS) is taught the history of biologics, the regulatory affairs and economic considerations, and their national/international use across the world. They are experts with strong clinical knowledge of the products for development and discussions with healthcare professionals, regulatory knowledge to help the products meet FDA guidelines and streamline approvals, and economic knowledge for reimbursements and place in the market. All of these factors ease the process for a pharmaceutical company to start adopting biosimilars into their product lineup. [5]

Conclusion

In the last 5 years, biosimilars have grown slowly but steadily in their ability to bridge the affordability gap that biologics created. As they are a relatively new addition to the healthcare system and drug markets, there’s still more room for them to expand in the market through pharma companies adopting them or new market entries using different business strategies for their competitive edge. With their current rate of growth, and a strong future projected for them in the coming years, more biosimilars will make their way into the international markets, and patient accessibility to biologic treatments should be less of an issue. Pharma companies would do themselves a great benefit by adding biosimilars to their research and development, as it could expand their market presence and give them new avenues to innovate modern healthcare in the near future. [4]

References:

1. Biologic Meds. The Real Cost of Biologic Drugs. Nov. 2024 https://biologicmeds.org/biologic-basics/the-real-cost-of-biologic-drugs/ 

2. American Cancer Society. What are Biosimilar Drugs?. Apr. 2022

https://www.cancer.org/cancer/managing-cancer/treatment-types/biosimilar-drugs/what-are-biosimilars.html

3. Biologics HQ. Samsung Bioepis Biosimilar Market Dynamics 7th Edition, Q4 2024. Sept. 2024

https://biologicshq.com/wp-content/uploads/2024/12/SB-Biosimilar-Market-Report-Q4-2024.pdf

4. Alira Health. Global Biosimilars Landscape in 2024: Trends, Challenges, and Opportunities. Accessed on Jan. 19, 2025

https://alirahealth.com/education-hub/global-biosimilars-landscape-in-2024-trends-challenges-and-opportunities/#:~:text=Global%20Biosimilars%20Market%20Growth,increasing%20number%20of%20biosimilar%20approvals.

5. ACMA. The Board Certified Biologics and Biosimilars Specialist Program (BCBBS®). 2025.

https://medicalaffairsspecialist.org/certifications/bcbbs

Categories
Blog

Mastering Pharmacology: A Game-Changer for Pharma Sales Reps Communicating with HCPs

Pharmacology is one of the most fundamental aspects of medication therapy. The absorption, distribution, metabolism, elimination, and mechanism of action of each drug must be considered by all healthcare professionals (HCPs) when deciding the best treatment regimen for their patients, making it a crucial factor in a drug’s development and success in the market. Without this information, providers can’t ensure the safety or efficacy of the medications they prescribe. Lacking this fundamental understanding as a sales rep can negatively impact a provider’s interest in a new product and their business relationship with the company. [1]

How can mastering pharmacology give sales reps a competitive advantage when meeting with prospective HCPs?

Pharmacology Knowledge in Action: Real-World Scenarios for Sales Rep Success

In a hypothetical scenario, a pharmaceutical sales rep is discussing a new drug with a  physician. The physician expresses concern about the accumulation of the drug in patients and possible interactions with other medications, especially in older patients with comorbid conditions and diminishing organ systems. He asks the sales rep several detailed questions about how the drug is absorbed, how it binds to its target receptors, how it’s metabolized, how it’s eliminated from the body, and how long it stays in the system. The sales rep only learned the market value of the drug and beneficial results of their company’s clinical trials and is unable to provide an adequate answer and instead recommends the physician refer to the company’s resources for the information. The physician reiterates how busy he is taking care of patients and that he doesn’t have the time to research this and eventually loses interest in the product. Due to limited knowledge of pharmacology, the sales rep failed to properly communicate and was unable to address the physician’s concerns. He returned to the company with no feedback, missing out on an opportunity and damaging credibility, ultimately having a negative impact on future business.

In an alternate scenario, this same physician is meeting with a sales rep from a different pharmaceutical company to discuss their new drug product. Once again, the physician’s main concern is the drug’s accumulation and prolonged concentration in his patient population, and he asks the sales rep to tell him about the drug’s binding, metabolism, and elimination. This sales rep, a Certified Pharmaceutical Representative, explains the drug’s full mechanism of action including its target receptors, then discusses its metabolism to its inactive metabolite via liver enzymes and renal elimination. The rep also elaborates on this concern with clinical trial results showing no significant side effects in older adults due to prolonged drug concentrations or toxicities. The physician sees that the sales rep has a good understanding of pharmacology to answer his questions and is more willing to voice his concerns. He asks a follow-up question to see if there are any drug interactions based on the product’s liver metabolism, and the sales rep can identify a specific enzyme it induces and some examples of medications that may be affected. The sales rep offers to look into that further to identify any other interactions that may be more common in the physician’s patient population. The physician asks the sales rep to stay in touch with any updates or findings.

This knowledgeable and proactive approach not only builds the physician’s interest in the product but also strengthens the trust and professional relationship between the provider and the company, paving the way for future collaboration and business opportunities, and directly contributing to the sales rep’s success. 

Pharmacology’s Role in Drug Marketing:

In both scenarios, the sales rep was informing the HCP about a new drug product and its shown benefits based on the clinical trials. The difference was, when asked about the details of the drug specifically, only one sales rep was able to adequately respond. As a result, the HCP wanted to inquire further about the drug, felt comfortable voicing his concerns knowing they’d be heard and understood, and was more willing to stay in touch about the product.

A sales representative with knowledge of pharmacology can communicate more effectively with healthcare professionals and is better equipped to recognize and address the barriers that prevent prescribers from adopting and marketing the products. Pharmaceutical sales teams with these well-informed or certified representatives give their companies a competitive edge in the market, allowing them to surpass the standard and show prospective HCPs that they put in the extra work and care to present their product and health information effectively and in detail. As mentioned, an understanding of a drug’s pharmacodynamics and pharmacokinetics, as well as its mechanism of action, is significant in the eyes of an HCP as it helps providers draw a connection from the product to their patient population so sales reps can better understand their clients’ needs. It also helps these companies to improve their product and their marketing since the reps can communicate any issues they hear, in detail, from the providers to the manufacturers, resulting in a superior formulation. 

There are also proactive ways to use this data for a sales pitch, such as:

  • Emphasizing a new mechanism of action or a metabolic pathway that produces fewer side effects compared to its competitors
  • Addressing concerns up front that might be relevant to the physician’s patient population so more time can be allocated to lesser-known obstacles
  • Providing maximum doses/infusion rates so the provider knows the product’s therapeutic range and toxicity potential

Certification as a Pharmaceutical Sales Representative:

A career as a pharmaceutical sales representative does not require a license or certification, but being certified ensures that a sales rep is well-versed in pharmacology before they step out into the field. ACMA offers two accredited certification programs that prepare representatives with knowledge of the pharma industry, the drug development process, healthcare economics and, most importantly, pharmacology. The Pharmaceutical Representative Certification (PRC) and the Certified Specialty Pharma Professional (CSPP) programs aim to “establish a baseline level of knowledge in core clinical areas” including pharmacology and mechanism of action, as a foundation of their content. [2] [4] [5]

The National Association of Pharmaceutical Sales Representatives also stresses the importance of understanding pharmacology to communicate effectively with physicians about their products, as it has become a standard of the industry, and sales experience alone is not enough to detail providers with the information that matters to them. Pharmaceutical companies value that certification when hiring new sales reps, while HCPs see that certification and those credentials and know that they are speaking to someone who will understand their perspective and convey it accurately to these drug manufacturers. [3] [6]

Conclusion: The Importance of Pharmacology and HCP Communication

Healthcare providers are the key customers for these drug manufacturers and their products. Effective communication between both groups is essential for breaking down barriers of access to their intended markets and minimizing issues to the target patient population. As pharmaceutical sales reps are directly in contact with both, they need to be able to bridge the gap between these two sides with a clear understanding of what each side wants. Pharmacology sits at the heart of drug therapy and determines how every patient gets treated, so having that same knowledge base sets a foundation for further discussion between the sales rep and the HCP and enables the representative to appropriately reflect the provider’s thoughts and feelings to the manufacturer. Detailed communication like this will keep HCPs in contact with these representatives knowing that their voices are being heard, and it will provide insightful feedback to the pharmaceutical companies to improve their products so they can reach more clients. Mastering pharmacology maximizes interactions between drug developers and healthcare providers, leading to better drug products and better patient outcomes.

References:

1. American Society for Pharmacology and Experimental Therapeutics (ASPET). Explore Pharmacology. 2022. https://www.aspet.org/docs/default-source/education-files/aspet_explore-pharmacology-2022_final7d540af399986662b1a8ff0000ef3f42.pdf?sfvrsn=1bcc6cd3_0 

2. Coursera Staff. A Guide to Pharmaceutical Sales Jobs: Salary, Resume, and Skills. Nov. 2023. https://www.coursera.org/articles/pharmaceutical-sales-jobs 

3. Pharma Sales. Mastering the Path to Pharma Sales Success: Your Ultimate Guide. Feb 2024. https://www.pharmasalestraining.org/2024/mastering-the-path-to-pharma-sales-success-your-ultimate-guide/

4. Pharma Sales Training. CSPP Program Information. Nov. 2023. https://www.pharmasalestraining.org/cspp-program-info/

5. Pharma Sales Training. PRC Program Information. Jan. 2021. https://www.pharmasalestraining.org/program/

6. The National Association of Pharmaceutical Sales Representatives. CNPR Pharmaceutical Sales Program. Accessed January 7, 2025. https://www.napsronline.org/cnpr-pharmaceutical-sales-program/ 

How can mastering pharmacology give sales reps a competitive advantage when meeting with prospective HCPs?

Pharmacology Knowledge in Action: Real-World Scenarios for Sales Rep Success

In a hypothetical scenario, a pharmaceutical sales rep is discussing a new drug with a  physician. The physician expresses concern about the accumulation of the drug in patients and possible interactions with other medications, especially in older patients with comorbid conditions and diminishing organ systems. He asks the sales rep several detailed questions about how the drug is absorbed, how it binds to its target receptors, how it’s metabolized, how it’s eliminated from the body, and how long it stays in the system. The sales rep only learned the market value of the drug and beneficial results of their company’s clinical trials and is unable to provide an adequate answer and instead recommends the physician refer to the company’s resources for the information. The physician reiterates how busy he is taking care of patients and that he doesn’t have the time to research this and eventually loses interest in the product. Due to limited knowledge of pharmacology, the sales rep failed to properly communicate and was unable to address the physician’s concerns. He returned to the company with no feedback, missing out on an opportunity and damaging credibility, ultimately having a negative impact on future business.

In an alternate scenario, this same physician is meeting with a sales rep from a different pharmaceutical company to discuss their new drug product. Once again, the physician’s main concern is the drug’s accumulation and prolonged concentration in his patient population, and he asks the sales rep to tell him about the drug’s binding, metabolism, and elimination. This sales rep, a Certified Pharmaceutical Representative, explains the drug’s full mechanism of action including its target receptors, then discusses its metabolism to its inactive metabolite via liver enzymes and renal elimination. The rep also elaborates on this concern with clinical trial results showing no significant side effects in older adults due to prolonged drug concentrations or toxicities. The physician sees that the sales rep has a good understanding of pharmacology to answer his questions and is more willing to voice his concerns. He asks a follow-up question to see if there are any drug interactions based on the product’s liver metabolism, and the sales rep can identify a specific enzyme it induces and some examples of medications that may be affected. The sales rep offers to look into that further to identify any other interactions that may be more common in the physician’s patient population. The physician asks the sales rep to stay in touch with any updates or findings.

This knowledgeable and proactive approach not only builds the physician’s interest in the product but also strengthens the trust and professional relationship between the provider and the company, paving the way for future collaboration and business opportunities, and directly contributing to the sales rep’s success. 

Pharmacology’s Role in Drug Marketing:

In both scenarios, the sales rep was informing the HCP about a new drug product and its shown benefits based on the clinical trials. The difference was, when asked about the details of the drug specifically, only one sales rep was able to adequately respond. As a result, the HCP wanted to inquire further about the drug, felt comfortable voicing his concerns knowing they’d be heard and understood, and was more willing to stay in touch about the product.

A sales representative with knowledge of pharmacology can communicate more effectively with healthcare professionals and is better equipped to recognize and address the barriers that prevent prescribers from adopting and marketing the products. Pharmaceutical sales teams with these well-informed or certified representatives give their companies a competitive edge in the market, allowing them to surpass the standard and show prospective HCPs that they put in the extra work and care to present their product and health information effectively and in detail. As mentioned, an understanding of a drug’s pharmacodynamics and pharmacokinetics, as well as its mechanism of action, is significant in the eyes of an HCP as it helps providers draw a connection from the product to their patient population so sales reps can better understand their clients’ needs. It also helps these companies to improve their product and their marketing since the reps can communicate any issues they hear, in detail, from the providers to the manufacturers, resulting in a superior formulation. 

There are also proactive ways to use this data for a sales pitch, such as:

  • Emphasizing a new mechanism of action or a metabolic pathway that produces fewer side effects compared to its competitors
  • Addressing concerns up front that might be relevant to the physician’s patient population so more time can be allocated to lesser-known obstacles
  • Providing maximum doses/infusion rates so the provider knows the product’s therapeutic range and toxicity potential

Certification as a Pharmaceutical Sales Representative:

A career as a pharmaceutical sales representative does not require a license or certification, but being certified ensures that a sales rep is well-versed in pharmacology before they step out into the field. ACMA offers two accredited certification programs that prepare representatives with knowledge of the pharma industry, the drug development process, healthcare economics and, most importantly, pharmacology. The Pharmaceutical Representative Certification (PRC) and the Certified Specialty Pharma Professional (CSPP) programs aim to “establish a baseline level of knowledge in core clinical areas” including pharmacology and mechanism of action, as a foundation of their content. [2] [4] [5]

The National Association of Pharmaceutical Sales Representatives also stresses the importance of understanding pharmacology to communicate effectively with physicians about their products, as it has become a standard of the industry, and sales experience alone is not enough to detail providers with the information that matters to them. Pharmaceutical companies value that certification when hiring new sales reps, while HCPs see that certification and those credentials and know that they are speaking to someone who will understand their perspective and convey it accurately to these drug manufacturers. [3] [6]

Conclusion: The Importance of Pharmacology and HCP Communication

Healthcare providers are the key customers for these drug manufacturers and their products. Effective communication between both groups is essential for breaking down barriers of access to their intended markets and minimizing issues to the target patient population. As pharmaceutical sales reps are directly in contact with both, they need to be able to bridge the gap between these two sides with a clear understanding of what each side wants. Pharmacology sits at the heart of drug therapy and determines how every patient gets treated, so having that same knowledge base sets a foundation for further discussion between the sales rep and the HCP and enables the representative to appropriately reflect the provider’s thoughts and feelings to the manufacturer. Detailed communication like this will keep HCPs in contact with these representatives knowing that their voices are being heard, and it will provide insightful feedback to the pharmaceutical companies to improve their products so they can reach more clients. Mastering pharmacology maximizes interactions between drug developers and healthcare providers, leading to better drug products and better patient outcomes.

References:

1. American Society for Pharmacology and Experimental Therapeutics (ASPET). Explore Pharmacology. 2022. https://www.aspet.org/docs/default-source/education-files/aspet_explore-pharmacology-2022_final7d540af399986662b1a8ff0000ef3f42.pdf?sfvrsn=1bcc6cd3_0 

2. Coursera Staff. A Guide to Pharmaceutical Sales Jobs: Salary, Resume, and Skills. Nov. 2023. https://www.coursera.org/articles/pharmaceutical-sales-jobs 

3. Pharma Sales. Mastering the Path to Pharma Sales Success: Your Ultimate Guide. Feb 2024. https://www.pharmasalestraining.org/2024/mastering-the-path-to-pharma-sales-success-your-ultimate-guide/

4. Pharma Sales Training. CSPP Program Information. Nov. 2023. https://www.pharmasalestraining.org/cspp-program-info/

5. Pharma Sales Training. PRC Program Information. Jan. 2021. https://www.pharmasalestraining.org/program/

6. The National Association of Pharmaceutical Sales Representatives. CNPR Pharmaceutical Sales Program. Accessed January 7, 2025. https://www.napsronline.org/cnpr-pharmaceutical-sales-program/